- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2009 (US).
- Why 3/10
- VIBATIV is an already-approved, marketed antibiotic with no pending FDA regulatory decision or pivotal readout in the next 12 months. The defining binary catalysts (initial FDA approvals in 2009 and 2013) are long past. The drug changed hands from Cumberland to Apotex in a July 2026 asset sale, and its commercial performance is now reported by a Canadian-listed company. No hard dated catalyst exists for this drug.
VIBATIV is a mature, approved antibiotic now owned by Apotex Health Corp. (TSX: APTX) following the July 2026 Cumberland asset sale. There are no upcoming FDA regulatory decisions or pivotal readouts for this drug. For US-listed investors, the drug's commercial performance is now reported by Apotex (Canadian-listed), not by any US-listed company. The previous US owner Cumberland (CPIX) has pivoted to a rare-disease pipeline focused on ifetroban.
Price Chart
Executive Summary
VIBATIV (telavancin) is an FDA-approved lipoglycopeptide antibiotic for complicated skin infections and hospital-acquired pneumonia caused by Gram-positive pathogens including MRSA. Originally developed by Theravance and approved in 2009/2013, it was later commercialized by Cumberland Pharmaceuticals (CPIX). In July 2026, Cumberland sold its entire U.S. branded commercial portfolio, including VIBATIV, to Apotex Health Corp. (TSX: APTX) in a $100M+ strategic transaction. The drug is now owned by Apotex, a Canadian company, and is a mature marketed product with no pending FDA regulatory catalysts. The filing hint linking VIBATIV to Zymeworks (ZYME) was incorrect.
How It Works
Telavancin is a potent injectable antibiotic that kills Gram-positive bacteria (including MRSA) by disrupting bacterial cell wall synthesis and damaging the bacterial cell membrane. It is a lipoglycopeptide, a modified form of the older antibiotic vancomycin with an added lipid tail that improves its potency and tissue penetration.
Trial Status
VIBATIV was originally FDA-approved in September 2009 for complicated skin and skin structure infections (cSSSI) and received a second approval in June 2013 for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus. A supplemental approval in May 2016 expanded the label. The drug has been on the market for over a decade and has been studied in multiple observational registries. In May 2026, it was launched in China following NMPA approval.
The Two-Sided Case
Upcoming Catalysts
- No upcoming FDA regulatory decisions or pivotal trial readouts for VIBATIV are scheduled. The drug is a mature commercial product.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zymeworks Inc. 8-K/A ZYME ·Originating report